Pharmacovigilance in Africa: Building Strategic Capability in a Maturing Regulatory Landscape

Pharmacovigilance in Africa: Building Strategic Capability in a Maturing Regulatory Landscape

Why Africa Is Becoming a Strategic Priority

Today, pharmaceutical companies entering African markets face a rapidly evolving environment. National Regulatory Authorities (NRAs) are strengthening oversight, reporting requirements are becoming more sophisticated, and regulators increasingly expect Marketing Authorization Holders (MAHs) to demonstrate robust, fully functioning pharmacovigilance (PV) systems.

This evolution comes at a pivotal moment.

Africa is projected to account for a significant share of global population growth by 2050, creating substantial demand for medicines and healthcare services. Clinical research activity continues to expand, while regulatory harmonization initiatives, including the African Medicines Agency (AMA), are laying the foundation for a more integrated pharmaceutical ecosystem.

Several countries have already reached WHO Global Benchmarking Tool (GBT) Maturity Level 3 or above, signalling a shift toward stronger and more predictable regulatory enforcement.

This combination — growth and regulation — creates a narrow window of opportunity.

For pharmaceutical companies, the opportunity is clear.

The complexity lies in managing compliance across multiple jurisdictions simultaneously.

A Regulatory Landscape That Is Evolving, But Not Yet Uniform

Africa is often described as a complex market for pharmacovigilance. In reality, it is a structured environment — just not yet uniform.

Across Africa, pharmacovigilance requirements are becoming increasingly aligned with international standards. MAHs are expected to maintain effective safety systems, submit Individual Case Safety Reports (ICSRs) within established timelines, and provide ongoing safety oversight through activities such as Periodic Safety Update Reports (PSURs), Development Safety Update Reports (DSURs), Risk Management Plans (RMPs), and signal detection.

Yet regulatory implementation remains country-specific.

Each market operates with its own level of maturity, documentation requirements, reporting timelines, and inspection practices. Many countries require a Local Person Responsible for Pharmacovigilance (LPPV) — sometimes referred to as a Local Safety Officer — who serves as the primary contact for regulators and ensures local compliance obligations are met.

For companies managing several African markets, this creates a significant operational burden.

The challenge is not regulation. The challenge is fragmentation.

Why This Matters Now

The regulatory landscape is evolving faster than many organizations realize.

As oversight increases and enforcement becomes more predictable, pharmacovigilance is moving from a back-office compliance activity to a business-critical capability. Companies that establish scalable PV frameworks early gain a significant advantage: they reduce regulatory risk, improve operational visibility, and create a stronger foundation for expansion.

In other words, pharmacovigilance is becoming a competitive differentiator — not simply a regulatory obligation.

Where Companies Commonly Struggle

The regulatory landscape is evolving faster than many organizations realize.

One of the most common misconceptions is that global pharmacovigilance structures can simply be extended into African markets without adaptation.

In practice, this approach often exposes organizations to unnecessary compliance risks.

A company may successfully launch products across several countries while relying on centralized global teams to manage safety reporting. Over time, local regulatory requirements begin to diverge from internal processes. Regulatory queries increase. Reporting timelines become more difficult to track. Responsibilities become fragmented across departments and external vendors.

The result is rarely a lack of expertise.

More often, it is a lack of operational structure.

Common Compliance Gaps

• Absence of a designated LPPV in countries where local representation is mandatory
• Delayed submission of expedited ICSRs within required 7- or 15-day timelines
• PSUR processes that do not account for country-specific requirements
• Inadequate local oversight of signal management activities
• Limited visibility over regulatory commitments across multiple jurisdictions

The solution is not adding more resources. It is redesigning the operating model.

The Hub Model: Scalable, Controlled, Compliant

A hub-based pharmacovigilance approach offers a more scalable and controlled alternative.

Instead of managing each country independently, companies can establish regional PV hubs— typically structured around major linguistic and regulatory clusters, such as Anglophone and Francophone Africa — to centralize case intake, reporting, oversight, and governance while maintaining local regulatory representation where required.

Local experts remain in place to ensure compliance with country-specific requirements, including LPPV obligations and direct regulatory interactions.

Key Benefits of a Hub-Based Approach

• Centralized governance with local regulatory compliance
• Greater consistency across markets
• Reduced operational complexity
• Improved visibility over safety activities
• Faster response to regulatory requests and inspections
• Cost efficiency without compromising compliance standards

Most importantly, it creates a framework that can scale as market presence expands.

How RegBridge Supports Pharmacovigilance Across Africa

At RegBridge, pharmacovigilance is approached as a long-term strategic capability rather than a collection of isolated compliance activities.

Our model combines regional coordination with local expertise, enabling MAHs to maintain regulatory compliance across multiple African markets without building fragmented infrastructures in every country.

Our Approach

• Establishing fully compliant PV systems aligned with ICH E2A/E2C guidelines and country-specific NRA requirements
• Deploying regional hub models covering Anglophone and Francophone markets
• Integrating local LPPVs and regulatory contacts in each market
• Supporting long-term lifecycle management, not just initial market entry
• Maintaining audit-ready documentation and supporting MAH inspections and NRA queries
• Continuous monitoring of evolving country-specific requirements

To provide both flexibility and predictability, our services are structured through a hybrid commercial model that combines ongoing retainers with milestone-based activities.

This approach gives clients greater visibility over costs while ensuring uninterrupted compliance support and long-term operational stability.

The Right Pharmacovigilance Structure Today Prevents Compliance Challenges Tomorrow

As regulatory expectations continue to evolve across Africa, organizations that proactively invest in scalable pharmacovigilance frameworks will be better positioned to maintain compliance, accelerate market growth, and navigate regulatory change with confidence.

Whether you are preparing for market entry, expanding into new territories, or optimizing existing PV operations, RegBridge can help you build a pharmacovigilance model aligned with both local requirements and global standards.

Speak with our team to explore a tailored pharmacovigilance strategy for your African markets.